

27th February 2026

Eastbourne District General Hospital
Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

1. How many patients has your Trust treated in the past 12 months (February 2025 - January 2026, or latest 12 months available) for Mantle Cell Lymphoma (MCL) (excluding patients being monitored but not undergoing active treatment)? In case you do not treat MCL, which other Trust do you refer patients needing treatment to?

30.

2. How many Mantle Cell Lymphoma (MCL) patients have been treated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

• BR (Bendamustine + rituximab)	3
• VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)	0
• R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)	2
• R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine)	1
• CVP (cyclophosphamide, vincristine and prednisolone)	0
• Brukinsa (zanubrutinib)	1
• Imbruvica (ibrutinib)	14
• Velcade (bortezomib) + chemotherapy	0
• Tecartus (brexucabtegene autoleucl)	0
• R-BAC (rituximab, bendamustine and cytarabine)	30
• R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)	0
• Any other systemic anti-cancer therapy	9
• Wait and watch (monitoring only, no active treatment) Section 12(1) applied, please see below.	-

East Sussex Healthcare NHS Trust does not centrally record patients as 'wait and watch (monitoring only, no active treatment)'. To enable the Trust to provide this information will require a manual review of patients' notes to establish if we hold this information, which

we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

3. How many Mantle Cell Lymphoma (MCL) new patients have been initiated by the Trust in the past 6 months (August 2025 - January 2026, or latest 6 months available) on the following treatments:

For this question, please only count patients that have received the below treatments for the first time.

•	BR (Bendamustine + rituximab)	2
•	VR-CAP (Bortezomib, Rituximab, Doxorubicin, Cyclophosphamide and prednisolone)	0
•	R-CHOP (Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone)	2
•	R-maxi-CHOP or Nordic Protocol (R-CHOP alternated with Rituximab+ High-dose Cytarabine)	1
•	CVP (cyclophosphamide, vincristine and prednisolone)	0
•	Brukinsa (zanubrutinib)	1
•	Imbruvica (ibrutinib)	0
•	Velcade (bortezomib) + chemotherapy	0
•	Tecartus (CAR-T)	0
•	R-BAC (rituximab, bendamustine and cytarabine)	0
•	R-DHAP (rituximab + cytarabine + cisplatin + dexamethasone)	0
•	Any other systemic anti-cancer therapy	1
•	Wait and watch (monitoring only, no active treatment) Section 12(1) applied, please refer to page 1.	-

4. If your Trust does treat Mantle Cell Lymphoma (MCL) patients, do you currently participate in any ongoing clinical trials for the treatment of MCL? If yes, please can you provide details of the ongoing trials.

[East Sussex Healthcare NHS Trust have no trials open to recruitment or in follow up for MCL.](#)

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm